The PCR-based assays run on the company's Aries system, which itself received FDA clearance in October 2015.
A month after Brexit fears pushed the GenomeWeb Index down half a percent, companies rallied on news of an acquisition and better than expected Q2 performances.
The point-of-care test detects and distinguishes influenza A and B as well as respiratory syncytial virus in about 20 minutes.
The company will soon submit its ePlex instrument and respiratory pathogen panel for US Food and Drug Administration clearance.
Speakers at the CVS meeting in Florida last week spoke about the utility and effectiveness of sequencing approaches in the study of viruses.
The firm recently made strategic hires with commercialization experience in anticipation of bringing its handheld point-of-care device to market.
The company said sales of its XT-8 molecular diagnostics system were strong, despite a lighter-than-expected flu season.
The state department has implemented WGS protocols for influenza A and B to track drug resistance and to better understand how the virus changes from year to year.
Researchers discussed using WGS to predict antibacterial resistance, to inform influenza vaccine development, and to diagnose and build drug resistance profiles for tuberculosis.
In PLOS this week: role of fibrillarin during henipavirus infection, ancestry patterns in Bene Israel individuals, and more.
Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.
The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.
Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.
In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.